Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11569029 | 0.88 | MAPT (0.63) | MAPTABL1POLBRIN1TDP1 | |
| SCHEMBL13422548 | 0.88 | MAPT (0.53) | MAPTABL1POLBRIN1TDP1 | |
| SCHEMBL800531 | 0.87 | MAPT (0.58) | MAPTABL1POLBRIN1TDP1 | |
| SCHEMBL5067988 | 0.86 | MAPT (0.56) | MAPTABL1POLBRIN1TDP1 | |
| SCHEMBL11568412 | 0.86 | MAPT (0.56) | MAPTABL1POLBRIN1TDP1 | |
| SCHEMBL13451568 | 0.82 | MAPT (0.52) | MAPTABL1POLBRIN1TDP1 | |
| SCHEMBL28137416 | 0.81 | MAPT (0.61) | MAPTABL1POLBRIN1TDP1 | |
| SCHEMBL10499987 | 0.80 | MEN1 (0.53) | MAPTCYP2C19TSHRCYP3A4 | |
| SCHEMBL19690767 | 0.79 | MAPT (0.48) | MAPTTSHRLMNAKDM4E | |
| SCHEMBL27442353 | 0.77 | MAPT (1.00) | MAPTABL1POLBRIN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0721452-B1 | PROCESS FOR THE PREPARATION OF SUFENTANIL DERIVATIVES BY CARBENE ADDITION/AMINOLYSIS OF 4-PIPERIDONE | MALLINCKRODT INC (US) | 2001-06-20 | — | — | EP | claimed |
| EP-0721452-A1 | PROCESS FOR THE PREPARATION OF SUFENTANIL DERIVATIVES BY CARBENE ADDITION/AMINOLYSIS OF 4-PIPERIDONE | Mallinckrodt Chemical, Inc. (US) | 1996-07-17 | — | — | EP | claimed |
| US-5489689-A | CONDENSING A PIPERIDONE WITH A PRIMARY AMINE TO FORM A 4-AMINO-4-CARBOXYAMINOPIPERIDINE; HYDROLYSIS; CONDENSATION WITH A MESYLATE CONTAINING A PHENYL, THIENYL OR 4-ETHYL-4,5-DIHYDRO-5-OXO-1H-TETRAZPINE | MALLINCKRODT CHEMICAL, INC. (US) | 1996-02-06 | — | — | US | claimed |
| WO-1995009152-A1 | PROCESS FOR THE PREPARATION OF SUFENTANIL DERIVATIVES BY CARBENE ADDITION/AMINOLYSIS OF 4-PIPERIDONE | MALLINCKRODT CHEMICAL, INC. (US) | 1995-04-06 | — | — | WO | claimed |
| EP-2616464-B1 | IMPROVED PROCESS FOR THE PREPARATION OF A PRECURSOR OF SUFENTANIL BASE | MALLINCKRODT LLC (US) | 2018-01-03 | — | — | EP | disclosed |
| US-8946433-B2 | Process for the preparation of sufentanil base and related compounds | MALLINCKRODT LLC (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2455377-B1 | Synthesis of fentanyl analogs | HAMELN RDS GMBH (DE) | 2014-07-09 | — | — | EP | disclosed |
| EP-2616464-A2 | IMPROVED PROCESS FOR THE PREPARATION OF SUFENTANIL BASE AND RELATED COMPOUNDS | Mallinckrodt LLC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20120071659-A1 | Process for the Preparation of Sufentanil Base and Related Compounds | MALLINCKRODT LLC (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2012037309-A2 | IMPROVED PROCESS FOR THE PREPARATION OF SUFENTANIL BASE AND RELATED COMPOUNDS | MALLINCKRODT LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-2044021-B1 | PROCESS FOR PREPARING REMIFENTANIL, INTERMEDIATES THEREOF, USE OF SAID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | KERN PHARMA S L (ES) | 2010-03-31 | — | — | EP | disclosed |
| US-20100016601-A1 | PROCESS FOR PREPARING REMIFENTANIL, INTERMEDIATES THEREOF, USE OF SAID INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF | KERN PHARMA, S.L. | 2010-01-21 | — | — | US | disclosed |
| EP-1246801-B1 | METHODS FOR THE SYNTHESES OF ALFENTANIL, SUFENTANIL AND REMIFENTANIL | MALLINCKRODT INC (US) | 2006-09-20 | — | — | EP | disclosed |
| US-7074935-B2 | Methods for the syntheses of alfentanil, sufentanil and remifentanil | MALLINCKRODT INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060149071-A1 | New methods for the synthesis of alfentanil, sufentanil, and remifentanil | MALLINCKRODT, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20040138461-A1 | Methods for the syntheses of alfentanil sufentanil and remifentanil | MALLINCKRODT, INC. | 2004-07-15 | — | — | US | disclosed |
| EP-1246801-A2 | METHODS FOR THE SYNTHESES OF ALFENTANIL, SUFENTANIL AND REMIFENTANIL | MALLINCKRODT INC. (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-0721452-B1 | PROCESS FOR THE PREPARATION OF SUFENTANIL DERIVATIVES BY CARBENE ADDITION/AMINOLYSIS OF 4-PIPERIDONE | MALLINCKRODT INC (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2001040184-A2 | METHODS FOR THE SYNTHESES OF ALFENTANIL, SUFENTANIL AND REMIFENTANIL | MALLINCKRODT INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| US-5489689-A | CONDENSING A PIPERIDONE WITH A PRIMARY AMINE TO FORM A 4-AMINO-4-CARBOXYAMINOPIPERIDINE; HYDROLYSIS; CONDENSATION WITH A MESYLATE CONTAINING A PHENYL, THIENYL OR 4-ETHYL-4,5-DIHYDRO-5-OXO-1H-TETRAZPINE | MALLINCKRODT CHEMICAL, INC. (US) | 1996-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149071-A1 | New methods for the synthesis of alfentanil, sufentanil, and remifentanil | OPRK1, OPRM1, OPRL1 | MAPT 2276/4885ABL1 1935/4885POLB 2767/4885 |
| US-20120071659-A1 | Process for the Preparation of Sufentanil Base and Related Compounds | SNRPD1, SNRPD2, SNRPA1 | MAPT 3645/4885ABL1 2020/4885POLB 1072/4885 |
| US-20040138461-A1 | Methods for the syntheses of alfentanil sufentanil and remifentanil | HNMT, OPRM1, ALKBH3 | MAPT 2666/4885ABL1 2365/4885POLB 1627/4885 |
| US-20100016601-A1 | PROCESS FOR PREPARING REMIFENTANIL, INTERMEDIATES THEREOF, USE OF SAID INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF | OPRK1, CYP3A43, CYP3A4 | MAPT 3123/4885ABL1 1660/4885POLB 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.